Clinical Trials Logo

Papulopustular Rosacea clinical trials

View clinical trials related to Papulopustular Rosacea.

Filter by:

NCT ID: NCT06013371 Recruiting - Clinical trials for Papulopustular Rosacea

PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea

Start date: June 30, 2023
Phase: Phase 2
Study type: Interventional

This study is a double-blind, vehicle-controlled clinical trial. The study will take place at Icahn School of Medicine at Mount Sinai. The study will include 33-39 adult subjects with moderate-to-severe-Seborrheic dermatitis (SD) as well as 33-39 adult subjects with moderate-to-severe papulopustular rosacea (PPR). Subjects will be randomized 2:1 to receive study drug or placebo. Enrolled subjects will apply topical PF-07038124 0.02% ointment once daily for 8 weeks. They will return for visits at weeks 4, 8, and 12 following study treatment initiation for repeat clinical assessments, medication reviews, tape-strip, blood and urine sample collections, and monitoring for adverse events.

NCT ID: NCT05838170 Completed - Clinical trials for Papulopustular Rosacea

Study of TP-04 in Participants With Papulopustular Rosacea

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

This study is being done to evaluate the safety, tolerability, and efficacy of the study drug, TP-04, in participants with papulopustular rosacea (PPR).

NCT ID: NCT05675501 Completed - Clinical trials for Papulopustular Rosacea

Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties

Start date: June 10, 2020
Phase: Phase 1
Study type: Interventional

The overall objective of this study is to assess how the use of the drug may shift the skin microbiome and skin biophysical properties. Specifically, the study objectives were to assess the following: - How the drug affects the skin microbiome compared with vehicle when applied once daily for 8 weeks in subjects with papulopustular rosacea. - How the drug affects the skin physical properties compared with vehicle when applied once daily for 8 weeks in subjects with papulopustular rosacea.

NCT ID: NCT05343455 Completed - Clinical trials for Papulopustular Rosacea

A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)

MVOR-2
Start date: March 29, 2022
Phase: Phase 3
Study type: Interventional

This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are diagnosed with moderate to severe papulopustular rosacea will be randomized in a 3:3:2 ratio to DFD-29 (40 mg), Doxycycline capsules 40 mg, or Placebo once daily for 16 weeks. Of the 320 subjects, approximately 160 subjects are planned to be enrolled at 15 sites in the US, while the remaining subjects are to be enrolled at 14 sites in the EU.

NCT ID: NCT05296629 Completed - Clinical trials for Papulopustular Rosacea

A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.

MVOR-1
Start date: March 14, 2022
Phase: Phase 3
Study type: Interventional

This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are diagnosed with moderate to severe papulopustular rosacea will be randomized in a 3:3:2 ratio to DFD-29 (40 mg), Doxycycline capsules 40 mg, or Placebo once daily for 16 weeks.

NCT ID: NCT05150587 Completed - Clinical trials for Papulopustular Rosacea

Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea

Start date: October 5, 2021
Phase: Phase 2
Study type: Interventional

Rosacea is a common chronic inflammatory relapsing-remitting skin condition almost exclusively affecting the central area of the face and the eyes. Preliminary evidence suggests that treatment with rifaximin, a poorly absorbed oral antibiotic drug may be beneficial in patients with rosacea, particularly in those with papulopustular phenotype and positivity to Lactulose Breath Test (L-BT). The objective of this study is twofold: 1. To explore the safety and efficacy of 2 doses of oral Rifaximin versus placebo in adults with moderate-to-severe papulopustular rosacea. 2. To assess the pharmacokinetics (PK) of these two dose regimens in a sub-group of patients.

NCT ID: NCT04731259 Suspended - Clinical trials for Papulopustular Rosacea

Study to Evaluate the Safety of ATR-04

Start date: January 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled phase 1b/2a study designed to evaluate the safety of an investigational product called ATR-04, to reduce the severity of epidermal growth factor receptor inhibitor (EGFRI) associated papulopustular rash on the face. This study will be performed at 10-12 clinical sites, with potentially a virtual component. Approximately 60 eligible subjects will participate. A subject's participation in the study will be up to a maximum of 86 days (up to 28 days for Screening, 28 days of BID treatment, and a 30 day no treatment follow-up period). The primary objective of this study is to evaluate the safety and tolerability of ATR-04 compared to placebo.

NCT ID: NCT03883945 Withdrawn - Clinical trials for Papulopustular Rosacea

A Safety and Efficacy Study to Evaluate Rosacea

Start date: July 2021
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety, efficacy, and pharmacokinetic profile of ascending concentrations of the study medication compared with vehicle in subjects with rosacea.

NCT ID: NCT03864978 Recruiting - Clinical trials for Papulopustular Rosacea

Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test

Start date: June 22, 2018
Phase: Phase 2
Study type: Interventional

Preliminary evidence suggests that treatment with rifaximin may be beneficial in patients with papulopustular rosacea. The present clinical trial is aimed to investigate the safety and efficacy of oral rifaximin delayed release versus placebo in adults with moderate-to-severe papulopustular rosacea (a.k.a. subtype II) and positive lactulose H2/CH4 breath test.

NCT ID: NCT03667222 Active, not recruiting - Clinical trials for Papulopustular Rosacea

Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea

PRISM
Start date: September 18, 2018
Phase: Phase 2
Study type: Interventional

This is a 12-week, multicenter, double-blind, randomized, two-arm, vehicle controlled study. Subjects will be randomized 1:1 to BPX-04 minocycline topical gel 1% or vehicle. This study will include approximately 176 randomized subjects with inflammatory lesions of papulopustular rosacea on the face, defined by an IGA score of 3 (moderate) or 4 (severe) at Baseline. Subjects will be healthy male or female subjects aged 18 years or older. There will be up to 20 study sites in the USA.